🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Laura J. van’t Veer

Laura J. van’t Veer

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts

Breast Cancer Research and Treatment(2020)10.1007/s10549-020-05611-8

N/A

0DataRank · unranked

23 citations

Michael Hauptmann, Ewout W. Steyerberg, Muriel A. Adank, Delal Akdeniz, Jannet Blom +52 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0DataRank · unranked

335 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy

Cancers(2022)10.3390/cancers14184436

N/A

0DataRank · unranked

23 citations

Nu N. Le, Natsuko Onishi, David C. Newitt, Lisa J. Wilmes, Jessica Gibbs +15 more

ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2313693120

N/A

0DataRank · unranked

70 citations

Volker Böhnert, Alby J. Joseph, Valentino Sudaryo, Gemini Skariah, Jason Swinderman +9 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.534

N/A

0DataRank · unranked

2 citations

Elizabeth Price, Sara J. Venters, Wěi Li, Denise M. Wolf, Jessica Gibbs +14 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

UNC Libraries(2024)10.17615/hwqw-2381

N/A

0DataRank · unranked

0 citations

R.A.E.M. Tollenaar, Carolien H. M. van Deurzen, Montserrat García‐Closas, U Eilber, Minouk J. Schoemaker +47 more

316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials

Annals of Oncology(2024)10.1016/j.annonc.2024.08.257

N/A

0DataRank · unranked

0 citations

Olof Danielsson, T. Fornander, Agneta Nordenskjöld, G. Pérez Tenorio, N.P. Tobin +6 more

315P Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer

Annals of Oncology(2024)10.1016/j.annonc.2024.08.256

N/A

0DataRank · unranked

0 citations

Huma Dar, Agneta Nordenskjöld, G. Pérez Tenorio, CC Yau, CC Benz +9 more

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer

medRxiv(2025)10.1101/2025.08.25.25334393

N/A

0DataRank · unranked

0 citations

James M. Dolezal, Hanna M. Hieromnimon, Sara J. Venters, Sara Kochanny, Anran Li +31 more

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy

Cancers(2020)10.3390/cancers12061511

N/A

0DataRank · unranked

18 citations

Deep Hathi, Rita I. Freimanis, Rita A. Mukhtar, A. Jo Chien, Laura J. Esserman +4 more